Title of article
Combination Therapy with Remdisivir and Tocilizumab for COVID-19: Lessons for Futures Studies
Author/Authors
Abbaspour Kasgari, Hamideh Department of Clinical Pharmacy - Mazandaran University of Medical Sciences, Sari , Babamahmoodi, Farhang Department of Infectious Disease - Mazandaran University of Medical Sciences, Sari , Davoudi Badabi, Ali Reza Department of Infectious Disease - Mazandaran University of Medical Sciences, Sari , Abbaskhani Davanloo, Ali Department of Anesthesiology - Mazandaran University of Medical Sciences, Sari , Moradimajd, Parisa Department of Anesthesia - Faculty of Allied Medical Sciences - Iran University of Medical Sciences, Tehran , Samaee, Hamidreza Department of Clinical Pharmacy - Mazandaran University of Medical Sciences, Sari
Pages
5
From page
1
To page
5
Abstract
The outbreak of (SARS-CoV-2) originated in Wuhan, China, and pneumonia induced by this virus is named coronavirus disease 2019 (Covid-19). By March 29, 2020, 737000 people were infected and 35000 died worldwide. To date, no effective medication is recommended to treat SARS-CoV-2 infection, and the drugs introduced are still in the clinical trial phase. Tocilizumab and Remdisivir are possible drugs to treat and improve the symptoms of the patients. We prescribed a combination of Remdisivir and Tocilizumab to treat three critical patients with Covid-19, and presented the results in this article. After the duration of treatment with this combination, one case was improved and discharged, but, unfortunately, two cases expired.
Keywords
Remdisivir , Tocilizumab , COVID-19 , Corona Virus
Journal title
Archives of Clinical Infectious Diseases
Serial Year
2020
Record number
2543906
Link To Document